Web Watch
Figures converted from TWD at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
Web Watch in One Page
Msscorps is a "Watchlist" name where the entire premium valuation (50.3× EV/EBITDA, ~5× direct peer MA-Tek) is paid up-front for two things that have not yet happened: a sustained FY2026 operating-margin recovery and a named hyperscaler-tier customer confirming the silicon-photonics / CPO "functional monopoly" claim. The five active web monitors below track exactly the disclosures that would resolve those open questions over the next 6–12 months — the Q2 FY26 earnings print in early August, monthly revenue prints from the Taiwan trio, named-customer or MSS HG equipment-launch disclosures, capital-structure moves around the outstanding ~$8.5M convertible bond, and the governance / Enli Technology patent-suit calendar that opens at the June 11 AGM.
Each monitor is tied to a specific report claim, catalyst, or "what would change the view" line — not a generic news feed. Together they cover the four threads an investor in this name actually has to underwrite: earnings cadence, AI/CPO narrative conversion, peer-share dynamics versus MA-Tek, and balance-sheet / governance risk.
Active Monitors
| Rank | Watch item | Cadence | Why it matters | What would be detected |
|---|---|---|---|---|
| 1 | Msscorps quarterly earnings and monthly revenue prints | Daily | Q2 FY26 (early August 2026) is the single decisive print — bull thesis needs sustained gross margin ≥ 25% and operating margin ≥ 10%; the monthly TWSE revenue prints around the 10th of each month are the highest-frequency read on whether the 4Q25 → 1Q26 margin reset reverses. | Each new monthly revenue release with year-over-year growth; quarterly earnings releases including margin and customer-concentration disclosures; FY26 revenue or capex guide updates; any pre-announcement or profit warning. |
| 2 | Named hyperscaler customer and MSS HG CPO inspection equipment milestones | Daily | The whole premium rests on confirming the "functional monopoly" claim. The April-2026 MSS HG silicon-photonics inspection platform debut and the rumoured AI-zone customer scaling from 25% to 75% of dedicated capacity are the load-bearing facts; a Nvidia / Broadcom / Marvell-tier name in a filing or trade-press confirmation is the re-rating switch. | Any new disclosure naming a hyperscaler counterparty (Nvidia, Broadcom, Marvell, Apple, AMD, Intel, etc.); first commercial MSS HG order, customer, pricing, or shipment; launch slip or pull-forward; CPO market-position commentary. |
| 3 | MA-Tek (3587.TWO) competitive moves and silicon-photonics commentary | Daily | MA-Tek is the only true peer — same niche, 2.6× the revenue, 2× the operating margin, 61% foreign-revenue mix. Its monthly revenue prints calibrate the share-gain question, and its chairwoman has already publicly pushed back on the silicon-photonics timing the Msscorps bull thesis relies on. | MA-Tek monthly revenue prints; quarterly earnings, margin or capex commentary; public chairwoman / CEO remarks on silicon photonics, co-packaged optics, AI inspection, or competitive position; new MA-Tek US / Japan lab announcements; named customer or patent disclosures touching the Msscorps niche. |
| 4 | Capital structure: convertible bond conversion, equity raises, dividend policy | Weekly | ~$8.5M of MSS I convertible bond is still outstanding at a $4.93 conversion price, FY25 FCF was negative ~$14.7M, debt-to-assets jumped from 39.7% to 46.9% in a single year, and the FY25 dividend was cut 78%. Any new financing event materially shifts the dilution and leverage thesis. | Incremental CB conversion or final redemption; any new equity raise, rights offering, or private placement; new bank borrowings or convertible bond issuance; changes to dividend policy; share buyback or treasury-share announcements; updates to FY26 capex guidance. |
| 5 | Governance, June 11 AGM, and Enli Technology patent litigation | Weekly | The June 11 AGM is the only scheduled forum to extract direct guidance on hyperscaler customers and MSS HG; the 2024 mid-cycle independent-director swap was a yellow flag the next AGM may repeat or resolve; the ~$6.7M Enli patent suit filed on March 25, 2026 is the first offensive test of the CPO IP that underwrites the bull moat leg. | AGM outcomes (director elections, independent-director changes, executive compensation, chairman remarks); senior executive departures (CFO, CTO, COO); any procedural ruling, settlement, counter-claim, or jurisdictional decision in the Enli Technology IP & Commercial Court case; new patent grants or oppositions in silicon-photonics / CPO methods. |
Why These Five
The five monitors map directly to the report's open questions. Monitor 1 is the catalysts tab's "single highest-impact event" (Q2 FY26 print) plus the moat tab's "first signal to watch" (monthly trio revenue divergence) — the two pieces of evidence that resolve whether 1Q26 was the bottom of the margin curve or the start of a peer-multiple compression. Monitor 2 tracks the named-customer disclosure and MSS HG launch that the verdict tab flags as the bull thesis' "re-rating switch" and the bear thesis' "12-month falsification window." Monitor 3 turns the competition tab's single most important peer comparison into a continuous read — MA-Tek's monthly prints and silicon-photonics commentary are the cleanest external test of the Msscorps moat claim. Monitor 4 covers the bear tab's "cash burn, leverage step-up, CB dilution overhang" thread that the variant tab notes is the single largest near-term downside risk. Monitor 5 activates around the June 11 AGM (29 days out at the time of writing) and stays on for the multi-year Enli IP litigation that defends the CPO patent leg of the moat. None of the five is generic; each one is tied to a dated claim, a specific catalyst, or a load-bearing assumption the price has already paid for.